Last updated 19 days ago
A Study to Investigate the Safety, Tolerability, Drug Levels and Drug Effects of BMS-986326 in Adult Participants With Different Forms of Lupus
60 patients around the world
Available in United States, Mexico, Argentina
Bristol-Myers Squibb
1Research sites
60Patients around the world
This study is for people with
Lupus
Cutaneous lupus erythematosus
Discoid lupus erythematosus
Systemic lupus erythematosus
Requirements for the patient
To 75 Years
All Gender
Medical requirements
- Having a diagnosis of Discoid Lupus Erythematosus (DLE), Subacute Cutaneous Lupus Erythematosus (SCLE), or Systemic Lupus Erythematosus (SLE).Participants with DLE or SCLE must have their diagnosis at least 3 months prior to screening and must be confirmed by biopsy (except if only the facial/head/neck region is affected) and must have some ongoing disease activity (based CLASI-A scoring).Participants with SLE must have a diagnosis of SLE at screening based on the 2019 EULAR/ACR Classification for SLE and have mild-moderate disease severity (based on a SLEDAI-2K score).
- SLE that is considered by the Investigator to be severe.Drug-induced CLE and drug-induced SLE.Women who are pregnant or breastfeeding.Current use of >10 mg prednisone (or equivalent) per day.
Sites
Clínica Adventista Belgrano - CABA - Buenos Aires
StudyIM0341000
SponsorBristol-Myers Squibb
Study typeInterventional
Conditions
LupusCutaneous lupus erythematosusDiscoid lupus erythematosusSystemic lupus erythematosus
Requirements
To 75 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT06013995
